ESiORin henkilöstön julkaisuja

Estimation of quality-adjusted survival with mild obstructive sleep apnoea and six quality of life (QoL) assessments: Comparison between trapezoid rule, cross-sectional and mixed model estimates

Soini E, Mäkirinne-Kallio N, Martikainen J et al. Estimation of quality-adjusted survival with mild obstructive sleep apnoea and six quality of life (QoL) assessments: Comparison between trapezoid rule, cross-sectional and mixed model estimates. 14th Biennial Society for Medical Decision Making (SMDM) European Meeting, Oslo. Program and abstracts 2012:158.

Scientific conference reference

Abstract e-book

Martikainen J, Soini E

Administration costs of intravenous biologic drugs for rheumatoid arthritis: Discrepancy between list cost prices and published costs

Soini E, Leussu M, Hallinen T. Administration costs of intravenous biologic drugs for rheumatoid arthritis: Discrepancy between list cost prices and published costs. 14th Biennial Society for Medical Decision Making (SMDM) European Meeting, Oslo. Program and abstracts 2012:223.

Scientific conference reference

Abstract e-book

Hallinen T, Soini E

Comparison of EQ-5D- and 15D-based quality-adjusted life-years (QALY) in patients with mild obstructive sleep apnoea (MOSA) using mixed modelling: Measurement tool and tariff matter

Soini EJ, Martikainen JA et al. Comparison of EQ-5D- and 15D-based quality-adjusted life-years (QALY) in patients with mild obstructive sleep apnoea (MOSA) using mixed modelling: Measurement tool and tariff matter. 14th Biennial Society for Medical Decision Making (SMDM) European Meeting, Oslo. Program and abstracts 2012:159.

Scientific conference reference

Abstract e-book

Martikainen J, Soini E

Uncertainty in computer simulation models. Economics, Modelling and Diabetes: The Sixth Mt Hood Challenge

Not available online

Asseburg C. Uncertainty in computer simulation models. Economics, Modelling and Diabetes: The Sixth Mt Hood Challenge. Baltimore, USA, Jun 7-8, 2012.

Scientific conference reference

On request

Asseburg C

Cost-utility of tocilizumab in the treatment of systemic juvenile idiopathic arthritis in Finland

Hallinen T, Soini E, et al. Cost-utility of tocilizumab in the treatment of systemic juvenile idiopathic arthritis in Finland. Annals of the Rheumatic Diseases 2013;71(Suppl3):258-9. Poster presented at the Annual European Congress of Rheumatology (EULAR) 2012, Berlin.

Scientific conference reference

Abstract

Hallinen T, Soini E

The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS)

Manca A, Asseburg C, et al. The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS). Value Health 2012;15(1):22-31.

Scientific publication

Open Access

Asseburg C

Dabigatraanin kustannusvaikuttavuus eteisvärinäpotilaiden aivohalvausten ehkäisyssä

Hallinen T, Soini E, et al. Dabigatraanin kustannusvaikuttavuus eteisvärinäpotilaiden aivohalvausten ehkäisyssä. Dosis 2012;28:130-44.

Scientific publication

Full text on Request

Hallinen T, Soini E

Cost-effectiveness of insulin glargine compared to other long-acting basal insulins in the treatment of Finnish type 1 and type 2 diabetes patients based on individual studies

Hallinen T, Soini E, et al. Cost-effectiveness of insulin glargine compared to other long-acting basal insulins in the treatment of Finnish type 1 and type 2 diabetes patients based on individual studies. Dosis 2012;28:145-64.

Scientific publication

Full text on Request

Hallinen T, Soini E

Sponsorship-Related Outcome Selection Bias in Published Economic Studies of Triptans: Systematic Review

Peura PK, Martikainen JA, et al. Sponsorship-Related Outcome Selection Bias in Published Economic Studies of Triptans: Systematic Review. Med Decis Making 2012;32(2):237-45.

Scientific publication

Abstract, Full text on Request

Martikainen J

Cost effectiveness of golimumab for the treatment of active psoriatic arthritis

Cummins E, Asseburg C, et al. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur J Health Econ 2012;13(6):801-9.

Scientific publication

Abstract, Full text on Request

Asseburg C

Contingent Valuation of Eight New Treatments: What is the Clinician’s and Politician’s Willingness to Pay?

Soini E, et al. Contingent Valuation of Eight New Treatments: What is the Clinician’s and Politician’s Willingness to Pay? The Open Complementary Medicine Journal 2012;4:1-11.

Scientific publication

PDF

Soini E

Economic evaluation of sequential treatments for follicular non-Hodgkin lymphoma

Soini E, Martikainen JA, et al. Economic evaluation of sequential treatments for follicular non-Hodgkin lymphoma. Clin Ther 2012;34(4):915-25.

Scientific publication

Abstract, Full text on Request

Martikainen J, Soini E

Hospitalisation utilisation and costs in schizophrenia patients in Finland before and after switch to risperidone long-acting injection

Asseburg C, et al. Hospitalisation utilisation and costs in schizophrenia patients in Finland before and after switch to risperidone long-acting injection. Schizophr Res Treatment 2012; 2012: 791468.

Scientific publication

Open Access

Asseburg C

Cost-effectiveness of adalimumab, etanercept and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis

Soini E, Hallinen TA, et al. Cost-effectiveness of adalimumab, etanercept and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ 2012;15(2):340-51.

Scientific publication

Abstract, Full text on Request

Hallinen T, Soini E

Triptaanien kustannusvaikuttavuus akuutin migreenikohtauksen hoidossa

Martikainen J, Asseburg C, et al. Triptaanien kustannusvaikuttavuus akuutin migreenikohtauksen hoidossa. Lääkealan turvallisuus- ja kehittämiskeskus Fimea. Fimea kehittää, arvioi ja informoi –julkaisusarja 1/2011.

Other publication

PDF

Asseburg C, Martikainen J

Value in Health Care. Key Information for Policymakers to Assess Efforts to Improve Quality While Reducing Costs

GAO. Value in Health Care. Key Information for Policymakers to Assess Efforts to Improve Quality While Reducing Costs. Washington: United States Government Accountability Office’s Report to Congressional Requesters, 2011. One of the responders: Soini, E.

Other publication

PDF

Soini E (responder/vastaaja)

Harvinaissairauksien taloudellinen arviointi: mitä päätöksien tueksi tulisi tuottaa?

Soini E. Harvinaissairauksien taloudellinen arviointi: mitä päätöksien tueksi tulisi tuottaa? Harvinaiset Sairaudet -lehti 2011;1:26-31.

Other publication

On request

Soini E

Mitä lääkehoitojen kustannusvaikuttavuus tarkoittaa?

Peura P, Turunen J, Purmonen T, Happonen P, Martikainen J. Mitä lääkehoitojen kustannusvaikuttavuus tarkoittaa? Sic! 2/2011

Other publication

Open Access

Martikainen J

Effectiveness and cost-effectiveness of antidepressants in primary care -a multiple treatment comparison meta-analysis and cost-effectiveness model

Ramsberg J, Asseburg C, Henriksson M. Effectiveness and cost-effectiveness of antidepressants in primary care -a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One 2012;7(8):e42003.

Scientific publication

Open Access

Asseburg C

Differential use of extended and immediate release quetiapine: A retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders

Hallinen T, Soini E, et al. Differential use of extended and immediate release quetiapine: A retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders. BMJ Open 2012;2(4):e000915.

Scientific publication

Open Access

Hallinen T, Soini E

Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison

Asseburg C, Peura P, Oksanen T, Turunen J, Purmonen T, Martikainen J. Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison. Int J Technol Assess Health Care 2012;28(4):382-9.

Scientific publication

Abstract, Full text on Request

Asseburg C, Martikainen J

Validation of Economic Simulation Models Using Clinical Trial Results: Experiences from Type 2 Diabetes Mellitus (T2DM)

Willis M, Asseburg C, He J. Validation of Economic Simulation Models Using Clinical Trial Results: Experiences from Type 2 Diabetes Mellitus (T2DM). iHEA 2011. Podium. J Med Econ 2013;16(8):1007-21.

Scientific conference reference

Abstract

Asseburg C

Initial HbA1c and HbA1c Lowering: Implications for Model-Based Economic Evaluations in Type 2 Diabetes Mellitus (T2DM)

Not available online

Willis M, Neslusan C, Asseburg C, et al. Initial HbA1c and HbA1c Lowering: Implications for Model-Based Economic Evaluations in Type 2 Diabetes Mellitus (T2DM). American Diabetes Association (ADA) meeting 2011. Podium.

Scientific conference reference

On request

Asseburg C

Cost-effectiveness of first-line rituximab maintenance treatment for follicular lymphoma

Soini E, Martikainen J, et al. Cost-effectiveness of first-line rituximab maintenance treatment for follicular lymphoma. Haematologica 2011;96(s2):402. Poster at the Annual Congress of European Hematology Association (EHA 2011).

Scientific conference reference

Abstract e-book

Martikainen J, Soini E

Terveystaloustrendiksi todellisen hoitotilanteen kustannusvaikuttavuus

Soini E. Terveystaloustrendiksi todellisen hoitotilanteen kustannusvaikuttavuus. Impulssi 2011;3:16-7.

Other publication

On request

Soini E

Myytkö lisäkustannuksia vai kustannusvaikuttavuutta?

Soini E. Myytkö lisäkustannuksia vai kustannusvaikuttavuutta? Podium 2011;5:19.

Other publication

On request

Soini E

Kokonaisuus ratkaisee kustannusvaikuttavuuden

Not available online

Kokonaisuus ratkaisee kustannusvaikuttavuuden. BI News 2011;syksy. Suomen Lääkärilehden välissä julkaistu tiedotuslehtinen. Haastateltu: Soini, E.

Other publication

On request

Soini E (interview/haastattelu)

Cost-Effectiveness of Targeted Therapy With Cetuximab in Patients With K-ras Wild-Type Colorectal Cancer Presenting With Initially Unresectable Metastases Limited to the Liver in a German Setting

Asseburg C, et al. Cost-Effectiveness of Targeted Therapy With Cetuximab in Patients With K-ras Wild-Type Colorectal Cancer Presenting With Initially Unresectable Metastases Limited to the Liver in a German Setting. Clin Ther 2011;33(4):482-97.

Scientific publication

Abstract, Full text on Request

Asseburg C

Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information

Soini E, et al. Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information. Ann Oncol 2011;22(1):215-23.

Scientific publication

Open Access

Soini E

Sequential treatment of follicular non-Hodgkin lymphoma: Cost-effectiveness and value of information

Soini E, Martikainen J, et al. Sequential treatment of follicular non-Hodgkin lymphoma: Cost-effectiveness and value of information. Value in Health 2011;14(7):A239-40. Podium at the Annual ISPOR European Congress.

Scientific conference reference

Abstract

Martikainen J, Soini E